ResMed Inc. (NYSE:RMD) Director Peter C. Farrell Sells 2,000 Shares

ResMed Inc. (NYSE:RMD) Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $242.11, for a total transaction of $484,220.00. Following the completion of the transaction, the director now owns 77,218 shares of the company’s stock, valued at $18,695,249.98. This trade represents a 2.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

ResMed Trading Down 0.1 %

ResMed stock opened at $236.84 on Friday. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12 month low of $170.56 and a 12 month high of $263.05. The stock’s 50 day simple moving average is $239.43 and its two-hundred day simple moving average is $237.19. The firm has a market cap of $34.77 billion, a PE ratio of 27.96, a P/E/G ratio of 1.69 and a beta of 0.70.

ResMed (NYSE:RMD) last released its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Analysts anticipate that ResMed Inc. will post 9.41 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be given a $0.53 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.90%. ResMed’s dividend payout ratio is presently 25.03%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. KeyCorp raised their price objective on shares of ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research report on Friday, January 31st. Royal Bank of Canada lifted their target price on shares of ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research report on Friday, October 25th. JPMorgan Chase & Co. boosted their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Piper Sandler lifted their target price on shares of ResMed from $252.00 to $260.00 and gave the stock a “neutral” rating in a research note on Friday, January 31st. Finally, UBS Group raised shares of ResMed from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and an average target price of $244.73.

Institutional Investors Weigh In On ResMed

Hedge funds have recently bought and sold shares of the stock. Cetera Investment Advisers raised its stake in shares of ResMed by 26.8% during the 2nd quarter. Cetera Investment Advisers now owns 9,721 shares of the medical equipment provider’s stock worth $1,861,000 after buying an additional 2,053 shares during the period. Sanctuary Advisors LLC acquired a new position in shares of ResMed during the 2nd quarter worth approximately $1,162,000. Czech National Bank raised its stake in shares of ResMed by 6.9% during the 3rd quarter. Czech National Bank now owns 29,931 shares of the medical equipment provider’s stock worth $7,307,000 after buying an additional 1,936 shares during the period. GAMMA Investing LLC raised its stake in shares of ResMed by 88.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,501 shares of the medical equipment provider’s stock worth $611,000 after buying an additional 1,177 shares during the period. Finally, Miracle Mile Advisors LLC acquired a new position in shares of ResMed during the 3rd quarter worth approximately $205,000. Hedge funds and other institutional investors own 54.98% of the company’s stock.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.